HSP90AB1 and breast cancer: Another therapeutic option for increasing the sensitivity of HER2+ breast cancer by blocking BCSCs and Wnt signaling is the use of Geldanamycin, a heat shock protein-90 kDa (HSP-90) inhibitor [132].